Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases

Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases

US Patent 7910108 · Granted Mar 22, 2011

Estimated economic value: $14,435,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Lyophilized compositions comprising arsenic2025
Asset tracking system and method2024
Asset tracking system and method2022
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)2022
Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors2020
High surface-area lyophilized compositions comprising arsenic for oral administr2020
High surface-area lyophilized compositions comprising arsenic for oral administr2019
High surface-area lyophilized compositions comprising arsenic for oral administr2018
Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors2018
Compositions, methods and kits relating to HER-2 cleavage2016
Compositions, methods and kits relating to HER-2 cleavage2016
Compositions, methods and kits relating to HER-2 cleavage2016